REDUCING THE RISK OF KIDNEY FAILURE IN CORONARY HEART DISEASE WITH THE REVOLUTIONARY IVUS TECHNOLOGY
Coronary Heart Disease today is a global epidemic that is rapidly spreading its devastation due to the sedentary nature of work, unhealthy lifestyles, untimely food, alcohol consumption, and other factors. It is the leading cause of high mortality in India. Of course, there is world-class treatment available to handle this dreaded disease. But not many people are aware of the fact that the presence of Coronary Artery Disease can lead to chronic ailments such as Contrast-Induced Nephropathy (CIN) and Chronic Kidney Failure (CKD).
In fact, Up to 40% of diabetic patients who undergo Angiogram are prone to CIN and an alarming 50-90% of them are affected by CKD. Global statistics indicate that the presence of Coronary Artery Disease in kidney failure patients is as high as 48%. In fact, it varies from 48% to 87% depending on the various stages of the disease. 2 out of every 10 CHD patients are detected with these problems and similarly, 5% of patients with kidney failure end up with Coronary Heart Disease.
To counter this situation, Medicover Hospitals, Hyderabad is embraced a revolutionary new technology called IVUS, which reduces the contrast volume during Angioplasty and reduces the risk of kidney failure. This procedure is being performed by renowned heart expert Dr. Sharath Reddy only at Medicover Hospitals, Hyderabad. In the press meet held at Medicover Hospitals today, Sr. Interventional Cardiologist, Dr. Sharath Reddy Says that he has taken up this unique challenge and evolved this path-breaking method of performing Angioplasty with minimal contrast through IVUS.
Actually, IVUS is an established coronary imaging method, which is being used for fine-tuning Coronary Angioplasty. Reduction of contrast volume significantly reduces contrast-induced kidney dysfunction which is well proven in various trials. This technique is largely underexplored by interventionists. Dr. Sharath has now devised a stepwise guided approach to reduce contrast use in a simple to complex angioplasty cases.
Over the last 2 years, he performed 24 Angioplasty cases with preexisting renal dysfunction. None of the patients have suffered progressive renal failure after the procedure. Extending Medicover Hospital’s track record of innovation and surgical excellence, this method of Angioplasty also reduces the duration of hospitalization and a need for renal replacement therapies. A boon for patients indeed.
